Voyageur Pharmaceuticals (TSXV:VM) Debt-to-Equity : 0.03 (As of Feb. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Voyageur Pharmaceuticals Debt-to-Equity?

Voyageur Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was C$0.00 Mil. Voyageur Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was C$0.04 Mil. Voyageur Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Feb. 2024 was C$1.58 Mil. Voyageur Pharmaceuticals's debt to equity for the quarter that ended in Feb. 2024 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Voyageur Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

TSXV:VM' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.56 Med: 0.06 Max: 0.88
Current: 0.03

During the past 13 years, the highest Debt-to-Equity Ratio of Voyageur Pharmaceuticals was 0.88. The lowest was -0.56. And the median was 0.06.

TSXV:VM's Debt-to-Equity is ranked better than
89.03% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs TSXV:VM: 0.03

Voyageur Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Voyageur Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyageur Pharmaceuticals Debt-to-Equity Chart

Voyageur Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Debt-to-Equity

Get a 7-Day Free Trial

0.18

0.88

0.02

0.03

Voyageur Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Debt-to-Equity	Get a 7-Day Free Trial															0.01	0.01	0.02	0.03	0.03

Competitive Comparison of Voyageur Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Voyageur Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Voyageur Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Voyageur Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Voyageur Pharmaceuticals's Debt-to-Equity falls into.

Voyageur Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Voyageur Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Nov. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0.04)	/	1.436
	=	0.03

Voyageur Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Feb. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0.04)	/	1.576
	=	0.03

Voyageur Pharmaceuticals (TSXV:VM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Voyageur Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Voyageur Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Voyageur Pharmaceuticals (TSXV:VM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Voyageur Pharmaceuticals Ltd (TSXV:VM) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

VYYRF:USA

Address

333 Southwest 7th Avenue, Suite 800, Calgary, AB, CAN, T2P 2Z1

Website

https://www.voyageurpharmaceuticals.ca

Voyageur Pharmaceuticals Ltd is engaged in the development of pharmaceutical ingredients (API) minerals. The company focuses on developing barium and iodine radiocontrast products and bromine-based pharmaceutical products. It provides its products for medical applications and diagnostics.

Voyageur Pharmaceuticals (TSXV:VM) Headlines

No Headlines